Skip to main content

Together we are beating cancer

Donate now

Cancer News

Latest News

Showing 12 out of 6228 results
A photograph of a mobile mammogram unit.

In this instalment of our Health Inequalities series, we take a look at some of the barriers that can make it harder for some people to access cancer screening. In this instalment of our Health Inequalities series, we take a look at some of the barriers that can make it harder for some people to access cancer screening.

by Julia Cotterill | Analysis | 23 September 2022

23 September 2022

This entry is part 4 of 5 in the series Health inequalities
%postcontent%
A photograph of someone holding a test tube in a lab.

We spoke to Dr Debbie Hicks about what is being done to understand and minimise the impact of long-term side effects for children and young people with medulloblastoma. We spoke to Dr Debbie Hicks about what is being done to understand and minimise the impact of long-term side effects for children and young people with medulloblastoma.

by Lilly Matson | Analysis | 22 September 2022

22 September 2022

The theme for this year’s Peer Review Week is ‘research integrity’ – that really strikes a chord with our new columnists… The theme for this year’s Peer Review Week is ‘research integrity’ – that really strikes a chord with our new columnists…

by Phil Prime | Analysis | 21 September 2022

21 September 2022

This entry is part 8 of 17 in the series Research Integrity
%postcontent%
A photo of Katie Currie with her mum and sister

In an unusual turn of events, the results of a clinical trial for mitoxantrone turned out to be so effective that the randomisation of the trial was halted early.  In an unusual turn of events, the results of a clinical trial for mitoxantrone turned out to be so effective that the randomisation of the trial was halted early. 

by Lilly Matson | Analysis | 16 September 2022

16 September 2022

A prostate cancer cell.

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

by Jacob Smith | News | 13 September 2022

13 September 2022

This entry is part 1 of 3 in the series CRUK Global
%postcontent%

This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers. This episode features Professor Richard Gilbertson. Richard is a paediatric oncology clinician scientist and is the Director of the Cancer Research UK Cambridge Centre. He talks about the challenges and successes of the childhood cancer research community, how he sees the future of the field and some of the incredible breakthroughs his lab has made on childhood brain cancers.

by Phil Prime | Podcast | 6 September 2022

6 September 2022

This entry is part 6 of 9 in the series Cancer Research Matters - series 1
%postcontent%